Company / SG&A Expense
Vera Therapeutics, Inc. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$100.2M
FY2025
5-year range
$11.9M / $100.2M
FY2021-FY2025
Trend
+144.4%
vs FY2024
Sector context
#113 of 213
Health Care
What the data says
At $100M, Vera Therapeutics, Inc.'s sg&a expense ranks #101 of 213 in the Health Care sector. SG&A Expense has increased for 5 consecutive years, from $4M in FY2020 to $100M in FY2025.
Based on SEC 10-K filings.
$100M in FY2025 with a 5-year CAGR of +90.1%.
Increased from $24M to $100M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +66.0%
- 5-Year CAGR
- +90.1%
- 10-Year CAGR
- -
Sector benchmark
#101 of 213 in Health CareTop 47% of 213This company $100.2M Sector average $722.3M
▼
-86.1% below sector average
Key checks
Key Insights
- Vera Therapeutics, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +90.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 144.4% year-over-year.
- Ranks #113 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $100.2M | +144.4% |
| FY2024 | $41.0M | +72.4% |
| FY2023 | $23.8M | +8.6% |
| FY2022 | $21.9M | +83.8% |
| FY2021 | $11.9M | +195.1% |
| FY2020 | $4.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026